Insider Selling: Jazz Pharmaceuticals plc (NASDAQ:JAZZ) CAO Sells 1,140 Shares of Stock

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) CAO Patricia Carr sold 1,140 shares of the business’s stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $137.81, for a total transaction of $157,103.40. Following the transaction, the chief accounting officer now owns 7,012 shares of the company’s stock, valued at approximately $966,323.72. This trade represents a 13.98 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Patricia Carr also recently made the following trade(s):

• On Thursday, February 27th, Patricia Carr sold 4,813 shares of Jazz Pharmaceuticals stock. The stock was sold at an average price of $144.42, for a total transaction of $695,093.46.

Jazz Pharmaceuticals Price Performance

Shares of NASDAQ:JAZZ traded down $0.59 during trading on Tuesday, reaching $136.86. The stock had a trading volume of 910,148 shares, compared to its average volume of 777,204. The business has a fifty day moving average price of $128.43 and a 200-day moving average price of $120.23. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. The stock has a market cap of $8.31 billion, a PE ratio of 19.28, a PEG ratio of 1.04 and a beta of 0.44. Jazz Pharmaceuticals plc has a 1-year low of $99.06 and a 1-year high of $148.06.

Hedge Funds Weigh In On Jazz Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the business. Mackenzie Financial Corp grew its position in shares of Jazz Pharmaceuticals by 493.3% in the fourth quarter. Mackenzie Financial Corp now owns 20,286 shares of the specialty pharmaceutical company’s stock valued at $2,498,000 after purchasing an additional 16,867 shares in the last quarter. Forum Financial Management LP acquired a new position in Jazz Pharmaceuticals in the 4th quarter valued at about $245,000. GF Fund Management CO. LTD. purchased a new stake in shares of Jazz Pharmaceuticals in the 4th quarter valued at approximately $156,000. MidWestOne Financial Group Inc. increased its stake in Jazz Pharmaceuticals by 10.4% during the fourth quarter. MidWestOne Financial Group Inc. now owns 24,347 shares of the specialty pharmaceutical company’s stock worth $2,998,000 after acquiring an additional 2,284 shares during the last quarter. Finally, Elequin Capital LP raised its holdings in Jazz Pharmaceuticals by 677.8% in the 4th quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company’s stock valued at $26,000 after buying an additional 183 shares during the period. 89.14% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts recently commented on JAZZ shares. Royal Bank of Canada lowered their target price on shares of Jazz Pharmaceuticals from $179.00 to $178.00 and set an “outperform” rating for the company in a research note on Wednesday, February 26th. Piper Sandler restated an “overweight” rating and issued a $176.00 price objective (up from $163.00) on shares of Jazz Pharmaceuticals in a research note on Wednesday, February 26th. Truist Financial increased their price objective on shares of Jazz Pharmaceuticals from $220.00 to $230.00 and gave the stock a “buy” rating in a research note on Thursday, March 6th. Robert W. Baird increased their price target on Jazz Pharmaceuticals from $154.00 to $162.00 and gave the stock an “outperform” rating in a research report on Monday, November 18th. Finally, JPMorgan Chase & Co. raised their target price on Jazz Pharmaceuticals from $200.00 to $209.00 and gave the stock an “overweight” rating in a report on Wednesday, February 26th. One analyst has rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Buy” and a consensus target price of $190.53.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.